Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | K0706 |
Synonyms | |
Therapy Description |
K0706 is a BCR-ABL kinase inhibitor with activity against the T315I mutation, which may demonstrate potential antineoplastic activity (PMID: 29866888, PMID: 31493432). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
K0706 | SUN K706|SUN-K0706|SUN-K706|Vodobatinib|WHO 11506|SCO-088 | BCR-ABL Inhibitor 32 | K0706 is a BCR-ABL kinase inhibitor with activity against the T315I mutation, which may demonstrate potential antineoplastic activity (PMID: 29866888, PMID: 31493432). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02629692 | Phase Ib/II | K0706 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to >=3 Prior CML Therapies | Active, not recruiting | USA | TUR | ROU | ITA | HUN | GBR | FRA | ESP | BEL | 2 |